Patients treated with intranasal FP had clinically and statistically significant decreases in ocular symptom scores compared with vehicle placebo. Data also suggest that FP reduced ocular symptoms more than or comparable with oral LOR. Patients experiencing ocular symptoms associated with allergic rhinitis may benefit from monotherapy with intranasal FP.

No abstract

Objective-To evaluate whether a p38␣/␤ mitogen-activated protein kinase inhibitor, SB-681323, would limit the elevation of an inflammatory marker, high-sensitivity C-reactive protein (hsCRP), after a percutaneous coronary intervention (PCI). Methods and Results-Coronary artery stents provide benefit by maintaining lumen patency but may incur vascular trauma and inflammation, leading to myocardial damage. A key mediator for such stress signaling is p38 mitogen-activated protein kinase. Patients with angiographically documented coronary artery disease receiving stable statin therapy and about to undergo PCI were randomly selected to receive SB-681323, 7.5 mg (nϭ46), or placebo (nϭ46) Key Words: angina pectoris Ⅲ atherosclerosis Ⅲ ischemia Ⅲ stent Ⅲ vascular biology Ⅲ inflammation P ercutaneous coronary intervention (PCI) has become the predominant form of coronary artery revascularization. 1 The benefits for resolution of chronic angina and/or salvation of ischemic myocardium during acute coronary syndromes are well documented. 2 However, PCI procedures can also injure the vessel wall, generating a considerable inflammatory response and smooth muscle cell proliferation, 3,4 culminating in restenosis at the lesion site (observed in 5% to 10% of subjects during the first year after PCI). 5,6

No abstract

Aims To determine the effects of sex and age on the pharmacokinetics of alosetron. Methods Single oral and intravenous 2 mg doses of alosetron were administered on separate occasions to 48 healthy, young and elderly, males and females. Serum was sampled for 12 h post-dose to measure alosetron concentrations. Results Serum concentrations of alosetron were higher in females than in males, resulting from a sex difference in clearance by metabolism. Mean clearance values were 504 vs 677 ml min x1 in young females vs males (mean ratio 0.75), and 461 vs 670 ml min x1 in elderly females vs males (mean ratio 0.69). The sex difference in alosetron pharmacokinetics achieved statistical signi®cance in the elderly, but not in the young. Irrespective of sex, alosetron clearance was increased by smoking. Serum concentrations tended to be higher in the elderly, although the effect of age was generally not signi®cant. Volume of distribution was smaller in females (approximately 63 l) compared with males (approximately 84 l), regardless of age or the sex difference in body weight. Conclusions A signi®cant difference in clearance by metabolism of alosetron between the sexes, and possibly between the young and elderly was observed.